
About Perthera
Perthera is a Healthcare company based in Mclean (United States) founded in 2012. Molecular cancer profiling is conducted via genomics and proteomics. Perthera has raised $17.02 million across 5 funding rounds from investors including Pilot Growth Equity Partners. The company has 13 employees. Perthera offers products and services including Perthera Report, Virtual Molecular Tumor Board, and RWE Data Pipeline. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its legal entity is PERTHERA INC. Its competitors include Denali Therapeutics, MiRagen and Tempus; 3 of its 3 listed competitors have raised funding.
Company details
Perthera was founded in 2012 and is based in McLean, United States, operating in the biotechnology sector focused on oncology. Personalized molecular profiling of tumors is facilitated through genomics and proteomics analyses. The PrecisOn process is employed to integrate these analyses with patient medical history in the Expert Oncologist system (ExpO), a database that incorporates current clinical research and drug information for oncologist guidance.
- Headquarters Mclean, United States
- Employees 13
- SectorsHealthcare
- Website perthera.com
- Social LinkedIn X Facebook
- Legal Name Perthera Inc.
- Total Equity Funding$17.02M (USD)
in 5 rounds
- Latest Funding Round$4.47M (USD), Series A
Sep 2022
- Investors
- Employee Count13
Products & Services of Perthera
Perthera offers a comprehensive portfolio of products and services, including Perthera Report, Virtual Molecular Tumor Board, and RWE Data Pipeline.
Ranks therapy options for cancer patients using AI analysis.
Facilitates physician collaboration for oncology expertise.
Processes real-world evidence for clinical trial matching.
Funding Insights of Perthera
Perthera has successfully raised a total of $17.02M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $4.47 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.02M
- Total Rounds 5
- Last Round Series A β $4.47M
- First Round $1.27M
(Aug 2015)
- Investors Count 1
All 5 funding rounds of Perthera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $4.47M | Series A | β | β | β |
| Jan 2019 | $2.1M | Series A | β | β | β |
| Jun 2016 | $9.17M | Series A | β | Pilot Growth Equity | β |
| Dec 2015 | $100,000 | Debt – Conventional | β | β | β |
| Aug 2015 | $1.27M | Seed | β | β | β |
1 investors in total: 1 institutional.
Investors in Perthera
Perthera has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Pilot Growth Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth equity investments are provided to technology entrepreneurs. | pilotgrowth.com | San Francisco, USA |
Investor details for Perthera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Perthera
20 people are tracked at Perthera (10 in leadership, 8 in board & advisors, 2 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Senait Fesseha | VP, Finance | Leadership |
Alex Stanwick | Director Healthcare Alliances/Oncology Sales | Leadership |
Aurelija Urbonaviciute | Director, Software Engineering | Leadership |
Nancy Tinnel Emrick | Vice President Operations | Leadership |
Michael Pishvaian | Chief Medical Officer | Leadership |
Edik Blais | Vice President Research | Leadership |
Patricia De Arbeloa | Medical Director | Leadership |
Aurelija Striuze | Director, European operations | Leadership |
Emanuel Petricoin | Chief Scientific Officer | Leadership |
Jeanne Cummins | Chief Marketing Officer (cmo) | Leadership |
Andrew Black | Board Member | Board & advisors |
John L. Marshall | Scientific Advisor | Board & advisors |
Jonathan Brody | Scientific Advisor | Board & advisors |
James Winnefeld Jr. | Senior Advisor | Board & advisors |
Yehuda Neuberger | Board Member | Board & advisors |
Einaras Von Gravrock | Board Member | Board & advisors |
Margot P. Schoenborn | Board Observer | Board & advisors |
Nan Hayworth | Board Member | Board & advisors |
Saulius Žemaitaitis | Software Engineer | Team |
Dzung Thach | Computational Biologist | Team |
Complete people profiles for Perthera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Perthera
3 dated milestones of Perthera across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Perthera is founded.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Series A, of $4.5M.
Competitors of Perthera
Perthera has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, MiRagen and Tempus.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| tempus.com | 2015 | Chicago, United States | $1.05B | 772 | AI-based precision medicine solutions for oncology are provided. |
Detailed competitors of Perthera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as Perthera (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Perthera
Complete news archive for Perthera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Perthera
Perthera was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Perthera is headquartered in Mclean, United States. It is registered at Mclean, Virginia, United States.
Perthera is a funded company, having raised a total of $17.02M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1.27M, raised on Aug 2015.
Perthera has 13 employees.
Perthera was founded in 2012 and is based in McLean, United States, operating in the biotechnology sector focused on oncology. Personalized molecular profiling of tumors is facilitated through genomics and proteomics analyses. The PrecisOn process is employed to integrate these analyses with patient medical history in the Expert Oncologist system (ExpO), a database that incorporates current clinical research and drug information for oncologist guidance.
Perthera's top competitors include Tempus, Denali Therapeutics and MiRagen.
Perthera offers Perthera Report, Virtual Molecular Tumor Board, and RWE Data Pipeline.
Perthera has 1 investor. Key investors include Pilot Growth Equity Partners.
Perthera operates through Perthera Inc..
